Medifocus Inc. (MDFZF) 0.1220 $MDFZF
SeeThruEquity Initiates Research Coverage on Medifocus Inc. with Target Price of $0.52
ACCESSWIRE - Wed Sep 03, 8:09AM CDT
New York, NY / ACCESSWIRE / September 3, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Medifocus, Inc. (TSXV: MFS.V and OTCQX: MDFZF), a healthcare company focused on developing and commercializing minimally invasive heat-based therapy systems for the treatment of cancerous and benign tumors.
Medifocus, Inc. Announces Financial Results for the Fiscal Year and Fiscal Fourth Quarter Ending March 31, 2014
Marketwire - Wed Jul 30, 8:54AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a revenue generating biotechnology company using focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, today announced its financial results for fiscal year and the fourth fiscal quarter ending March 31, 2014. Sales from its Prolieve(R) Thermodilatation System, reached $5,383,973 for the fiscal year ended March 31, 2014, representing an increase of 198% from the prior year. In July 2012, Medifocus acquired the Prolieve(R) business from Boston Scientific Corporation and recorded revenues of $1,805,969 from Prolieve for the Fiscal Year ended March 31, 2013. The net loss before other charges for the year was $5,222,429, a decrease of $374,043, or 7%, from the previous year primarily due to the revenue growth.
Medifocus, Inc. Is Issued New U.S. Patent Titled, "Apparatus and Method for Pre-Conditioning /Fixation and Treatment of Disease With Heat Activation/Release With Thermoactivated Drugs and Gene Pr
Marketwire Canada - Wed Jul 09, 10:25AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that on July 1st, 2014, it was issued a new patent by the United States Patent and Trademark Office (USPTO). Medifocus owns an extensive and valuable patent portfolio of over 100 USA and International patents all related to the usage and method of heating technologies to treat diseases almost anywhere within the body.
Medifocus, Inc. Is Issued New U.S. Patent Titled, "Apparatus and Method for Pre-Conditioning /Fixation and Treatment of Disease With Heat Activation/Release With Thermoactivated Drugs and Gene Products"
Marketwire - Wed Jul 09, 10:25AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that on July 1st, 2014, it was issued a new patent by the United States Patent and Trademark Office (USPTO). Medifocus owns an extensive and valuable patent portfolio of over 100 USA and International patents all related to the usage and method of heating technologies to treat diseases almost anywhere within the body.
Medifocus, Inc. Featured in Article in "BioTuesdays" Titled, "Medifocus Readies Marketing Expansion of Prolieve"
Marketwire Canada - Tue Jul 08, 11:02AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it is featured in today's BioTuesday titled, "Medifocus Readies Market Expansion of Prolieve." Prolieve is a FDA-Approved commercial device for the treatment of symptoms caused by the enlargement of the prostate, which is known as Benign Prostatic Hyperplasia (BPH). The full article can be read on www.biotuesdays.com
Medifocus Inc. Announces Extension of Warrants
Marketwire - Wed Jun 18, 1:29AM CDT
Medifocus Inc. (Medifocus or the Company) (TSX VENTURE: MFS)(OTCQX: MDFZF) is pleased to announce that it has applied to the TSX Venture Exchange (the Exchange) to extend the expiry date of 13,056,997 outstanding common share purchase warrants issued pursuant to the private placement announced November 30, 2012 and to extend the expiry date of 22,196,795 outstanding common share purchase warrants issued pursuant to the private placement announced July 6, 2012 by one year. Both sets of warrants entitle the holder thereof to acquire one common share of Medifocus at a price of $0.20.
Medifocus, Inc. Expands Its Reach Into the Asia-Pacific Market With the Engagement of Euro Japan Marketing Ltd. and Maxim Group, LLC
Marketwire - Mon Mar 17, 7:31AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, is pleased to announce that Medifocus Asia, Ltd. has entered into an advisory agreement with Euro Japan Marketing Ltd. and Maxim Group, LLC to help identify distribution and joint venture partners for the Company's cutting-edge Prolieve(R) Thermodilatation System in Japan and South Korea.
Medifocus, Inc. to Make Clinical Presentation at 24th Annual National Interdisciplinary Breast Center Conference
Marketwire Canada - Wed Mar 12, 8:11AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that a clinical poster presentation of the Company's breast cancer treatment system, the Microfocus APA 1000, will be made at the 24th Annual National Interdisciplinary Breast Center Conference, March 15-19, 2014 in Las Vegas, NV.
Medifocus, Inc. Announces $2 Million Second Tranche Closing of $6 Million Convertible Debenture Financing
Marketwire - Tue Mar 11, 7:58AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the closing of the second tranche of $2 million of its previously announced $6 million convertible debenture financing. The first tranche of $3,540,000 was completed on December 18, 2013.
Medifocus, Inc. Obtains Newly Allowed European Patent Office (EPO) Patent on the Treatment and Prevention of Breast Cancer
Marketwire Canada - Thu Mar 06, 9:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) and (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, is pleased to announce that it has obtained a newly allowed European Patent Office (EPO) patent to add to its extensive intellectual property portfolio of over 100 issued and/or pending U.S. and foreign patents covering its two thermotherapy platform technologies for the treatments of breast cancer and prostate diseases.
Medifocus, Inc. Announces Financial Results for the Third Fiscal Quarter and Nine Months Ending December 31, 2013
Marketwire - Thu Mar 06, 7:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, today announced its financial results for the third fiscal quarter and nine months ending December 31, 2013.
Medifocus Inc. Announces Extension of Convertible Debenture Financing
Marketwire - Fri Feb 14, 3:46PM CST
Medifocus Inc. (TSX VENTURE: MFS)(OTCQX: MDFZF) announced today a further extension of the final closing of its non-brokered private placement (the Offering) of $6,000,000 previously announced in August 2013. The Company previously disclosed the completion of the first tranche of the Offering, in an amount of $3,540,000, on December 18, 2013 and now expects to complete the Offering by February 28, 2014. All other terms and conditions of the Offering remain unchanged.
SeeThruEquity Initiates Research Coverage on Medifocus Inc. with Target Price of $0.52
ACCESSWIRE - Wed Sep 03, 8:09AM CDT
New York, NY / ACCESSWIRE / September 3, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Medifocus, Inc. (TSXV: MFS.V and OTCQX: MDFZF), a healthcare company focused on developing and commercializing minimally invasive heat-based therapy systems for the treatment of cancerous and benign tumors.
Medifocus, Inc. Announces Financial Results for the Fiscal Year and Fiscal Fourth Quarter Ending March 31, 2014
Marketwire - Wed Jul 30, 8:54AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a revenue generating biotechnology company using focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, today announced its financial results for fiscal year and the fourth fiscal quarter ending March 31, 2014. Sales from its Prolieve(R) Thermodilatation System, reached $5,383,973 for the fiscal year ended March 31, 2014, representing an increase of 198% from the prior year. In July 2012, Medifocus acquired the Prolieve(R) business from Boston Scientific Corporation and recorded revenues of $1,805,969 from Prolieve for the Fiscal Year ended March 31, 2013. The net loss before other charges for the year was $5,222,429, a decrease of $374,043, or 7%, from the previous year primarily due to the revenue growth.
Medifocus, Inc. Is Issued New U.S. Patent Titled, "Apparatus and Method for Pre-Conditioning /Fixation and Treatment of Disease With Heat Activation/Release With Thermoactivated Drugs and Gene Pr
Marketwire Canada - Wed Jul 09, 10:25AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that on July 1st, 2014, it was issued a new patent by the United States Patent and Trademark Office (USPTO). Medifocus owns an extensive and valuable patent portfolio of over 100 USA and International patents all related to the usage and method of heating technologies to treat diseases almost anywhere within the body.
Medifocus, Inc. Is Issued New U.S. Patent Titled, "Apparatus and Method for Pre-Conditioning /Fixation and Treatment of Disease With Heat Activation/Release With Thermoactivated Drugs and Gene Products"
Marketwire - Wed Jul 09, 10:25AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that on July 1st, 2014, it was issued a new patent by the United States Patent and Trademark Office (USPTO). Medifocus owns an extensive and valuable patent portfolio of over 100 USA and International patents all related to the usage and method of heating technologies to treat diseases almost anywhere within the body.
Medifocus, Inc. Featured in Article in "BioTuesdays" Titled, "Medifocus Readies Marketing Expansion of Prolieve"
Marketwire Canada - Tue Jul 08, 11:02AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it is featured in today's BioTuesday titled, "Medifocus Readies Market Expansion of Prolieve." Prolieve is a FDA-Approved commercial device for the treatment of symptoms caused by the enlargement of the prostate, which is known as Benign Prostatic Hyperplasia (BPH). The full article can be read on www.biotuesdays.com
Medifocus Inc. Announces Extension of Warrants
Marketwire - Wed Jun 18, 1:29AM CDT
Medifocus Inc. (Medifocus or the Company) (TSX VENTURE: MFS)(OTCQX: MDFZF) is pleased to announce that it has applied to the TSX Venture Exchange (the Exchange) to extend the expiry date of 13,056,997 outstanding common share purchase warrants issued pursuant to the private placement announced November 30, 2012 and to extend the expiry date of 22,196,795 outstanding common share purchase warrants issued pursuant to the private placement announced July 6, 2012 by one year. Both sets of warrants entitle the holder thereof to acquire one common share of Medifocus at a price of $0.20.
Medifocus, Inc. Expands Its Reach Into the Asia-Pacific Market With the Engagement of Euro Japan Marketing Ltd. and Maxim Group, LLC
Marketwire - Mon Mar 17, 7:31AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, is pleased to announce that Medifocus Asia, Ltd. has entered into an advisory agreement with Euro Japan Marketing Ltd. and Maxim Group, LLC to help identify distribution and joint venture partners for the Company's cutting-edge Prolieve(R) Thermodilatation System in Japan and South Korea.
Medifocus, Inc. to Make Clinical Presentation at 24th Annual National Interdisciplinary Breast Center Conference
Marketwire Canada - Wed Mar 12, 8:11AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that a clinical poster presentation of the Company's breast cancer treatment system, the Microfocus APA 1000, will be made at the 24th Annual National Interdisciplinary Breast Center Conference, March 15-19, 2014 in Las Vegas, NV.
Medifocus, Inc. Announces $2 Million Second Tranche Closing of $6 Million Convertible Debenture Financing
Marketwire - Tue Mar 11, 7:58AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the closing of the second tranche of $2 million of its previously announced $6 million convertible debenture financing. The first tranche of $3,540,000 was completed on December 18, 2013.
Medifocus, Inc. Obtains Newly Allowed European Patent Office (EPO) Patent on the Treatment and Prevention of Breast Cancer
Marketwire Canada - Thu Mar 06, 9:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) and (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, is pleased to announce that it has obtained a newly allowed European Patent Office (EPO) patent to add to its extensive intellectual property portfolio of over 100 issued and/or pending U.S. and foreign patents covering its two thermotherapy platform technologies for the treatments of breast cancer and prostate diseases.
Medifocus, Inc. Announces Financial Results for the Third Fiscal Quarter and Nine Months Ending December 31, 2013
Marketwire - Thu Mar 06, 7:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, today announced its financial results for the third fiscal quarter and nine months ending December 31, 2013.
Medifocus Inc. Announces Extension of Convertible Debenture Financing
Marketwire - Fri Feb 14, 3:46PM CST
Medifocus Inc. (TSX VENTURE: MFS)(OTCQX: MDFZF) announced today a further extension of the final closing of its non-brokered private placement (the Offering) of $6,000,000 previously announced in August 2013. The Company previously disclosed the completion of the first tranche of the Offering, in an amount of $3,540,000, on December 18, 2013 and now expects to complete the Offering by February 28, 2014. All other terms and conditions of the Offering remain unchanged.
